Latest & greatest articles for alopecia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alopecia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alopecia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alopecia

1. Variant PADI3 in Central Centrifugal Cicatricial Alopecia. (PubMed)

Variant PADI3 in Central Centrifugal Cicatricial Alopecia. Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia among women of African ancestry. The disease is occasionally observed to affect women in families in a manner that suggests an autosomal dominant trait and usually manifests clinically after intense hair grooming. We sought to determine whether there exists a genetic basis of CCCA and, if so, what it is.We used exome sequencing in a group (...) of women with alopecia (discovery set), compared the results with those in a public repository, and applied other filtering criteria to identify candidate genes. We then performed direct sequencing to identify disease-associated DNA variations and RNA sequencing, protein modeling, immunofluorescence staining, immunoblotting, and an enzymatic assay to evaluate the consequences of potential etiologic mutations. We used a replication set that consisted of women with CCCA to confirm the data obtained

2019 NEJM

2. A new therapy for alopecia areata using fire needles: a systematic review and meta-analysis of randomised controlled trials

A new therapy for alopecia areata using fire needles: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

3. Premature alopecia and risk of cardiovascular diseases (CVD): a systematic review and meta-analysis of the currently available literature

Premature alopecia and risk of cardiovascular diseases (CVD): a systematic review and meta-analysis of the currently available literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

4. A systematic review and network meta-analysis of non-surgical interventions for androgenetic alopecia

A systematic review and network meta-analysis of non-surgical interventions for androgenetic alopecia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

5. What are the unmet supportive care needs of men and women affected by chemotherapy induced alopecia? A systematic review

What are the unmet supportive care needs of men and women affected by chemotherapy induced alopecia? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

6. Alopecia

Alopecia Top results for alopecia - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alopecia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

7. Alopecia areata

Alopecia areata Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

8. Alopecia

Alopecia Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

9. Review of quality of life studies in women with alopecia (PubMed)

Review of quality of life studies in women with alopecia Alopecia is a dermatologic condition that affects the pilosebaceous unit in both men and women. In addition to a thorough medical history and physical examination, a host of diagnostic tools may be warranted to differentiate nonscarring and scarring alopecias. Female pattern hair loss represents the most common form of hair loss experienced by up to 40% of women by a certain age. Although alopecia is a benign disorder, even the most (...) negligible amount of hair loss can be devastating to a patient's self-esteem, self-image, and overall quality of life. We present this comprehensive review of quality of life studies in women with alopecia to describe the multitude of feelings and emotions associated with the disorder and remind dermatologists of the psychological impact it can have on women.

Full Text available with Trip Pro

2018 International journal of women's dermatology

10. Androgenic alopecia

Androgenic alopecia Androgenic alopecia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Androgenic alopecia Last reviewed: February 2019 Last updated: March 2018 Summary Also known as pattern baldness, androgenic alopecia is a genetically determined, patterned, progressive loss of hair from the scalp and occurs in both men and women. Both androgens and genetics play a role in its pathogenesis. The term androgenic (...) alopecia is best used only when referring to male-pattern hair loss, as most females likely do not share the androgenic pathway. A more appropriate term for women is female-pattern hair loss. The term pattern hair loss will be used when referring to hair loss affecting both sexes. Men present with hair thinning in the temporal areas that advances to the crown (vertex) area as the alopecia progresses. Women usually have more diffuse thinning on the crown area, and less commonly present with a male-type

2018 BMJ Best Practice

11. Alopecia, androgenetic - male

Alopecia, androgenetic - male Alopecia, androgenetic - male - NICE CKS Share Alopecia, androgenetic - male: Summary Androgenetic alopecia describes a distinctive pattern of hair loss, which may occur in genetically predisposed men and is thought to be androgen dependent. In men, hair loss usually initially involves the front and sides of the scalp and progresses towards the back of the head. The underlying pathological process involves pigmented terminal hairs gradually being replaced (...) by smaller, less pigmented hairs similar to vellus hairs. Male androgenetic alopecia is thought to be a polygenic disorder. It is thought that in genetically predisposed hair follicles there are increased numbers of androgen receptors and/or increased activity of 5-alpha reductase, an enzyme which mediates the effects of androgens on scalp hair. The prevalence and the severity of androgenetic alopecia is highest in white men, tends to occur less in black men, and later and more slowly in Asian men. By 30

2018 NICE Clinical Knowledge Summaries

12. Alopecia areata

Alopecia areata Alopecia areata - NICE CKS Share Alopecia areata: Summary Alopecia areata is a chronic, inflammatory condition affecting the hair follicles which leads to sudden onset of non-scarring alopecia (hair loss where the hair follicles are generally preserved). Any hair-bearing skin can be involved, but it most commonly affects the scalp or beard and, less frequently, the eyebrows and eyelashes. Total loss of scalp hair (alopecia totalis) or scalp and body hair (alopecia universalis (...) ) is rare. Nail changes are seen in 10–15% of people. Alopecia areata occurs when hairs are prematurely converted from the growth (anagen) to the loss (telogen) phase, but the exact cause is unknown. Alopecia areata is a relatively common condition and is estimated to affect 15 in 10,000 people in the UK. It can present at any age, and males and females are affected equally. The prognosis of alopecia areata is unpredictable. Spontaneous remission within one year may be seen in up to 80% of people

2018 NICE Clinical Knowledge Summaries

13. Quality of life in mild and severe alopecia areata patients (PubMed)

Quality of life in mild and severe alopecia areata patients Alopecia areata is a relapsing hair disorder characterized by a sudden hairloss and has a considerable impact on patient's quality of life. The goal of this study was to determine quality of life among patients with mild and severe forms of alopecia areata and compare the two groups.During one year, 176 patients (96 mild, 80 severe) were selected and asked to complete Dermatology Life Quality Index (DLQI) questionnaires.Our study (...) confirms that alopecia areata considerably impacts quality of life and this is more pronounced in patients with severe disease and those who had acute stress recently.

Full Text available with Trip Pro

2017 International journal of women's dermatology

14. Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series (PubMed)

Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series Alopecia universalis is an autoimmune disorder for which there is no known effective therapy. Tofacitinib-a novel antirheumatic therapy for rheumatoid arthritis-has been shown in some reports to induce sustained hair growth in patients with alopecia universalis.Here, we review the experiences of four different rheumatologists across the country regarding four Brazilian (...) patients with alopecia universalis who were treated with tofacitinib . Two of these four patients had idiopathic alopecia and the other two had rheumatoid arthritis; in each case, the alopecia universalis was apparently induced by etanercept.Tofacitinib should be considered for the treatment of severe alopecia areata, but the optimal dose and duration of therapy should be defined in randomized controlled trials.

Full Text available with Trip Pro

2017 Rheumatology and therapy

15. Injections of Platelet-Rich Plasma for androgenic alopecia: A systematic review. (PubMed)

Injections of Platelet-Rich Plasma for androgenic alopecia: A systematic review. The aim of this literature review was to evaluate the effects of PRP injections into the scalp of patients with androgenic alopecia. A literature review was conducted using the Pubmed and Google Scholar databases with the search terms "platelet-rich plasma" or "platelet-rich fibrin" and "hair" or "alopecia" or "androgenic alopecia". The publications included had to clinically assess the efficacy of PRP injections (...) in patients with androgenic alopecia. Out of the 32 publications retrieved, 14 publications were included, of which 3 randomized, 4 prospective controlled, 4 prospective uncontrolled and 3 retrospective studies. Seven out of 9 studies reported a significant increase of hair density ranging between 12.3 and 45.9 hairs/cm2, (i.e. 19-31% hairs/cm2). Four studies assessed hair loss with the traction test and found a negative result after treatment in more than 95% of patients. Regarding hair thickness, 1

2017 Journal of stomatology, oral and maxillofacial surgery

16. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. (PubMed)

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes (...) months). No participants in the scalp cooling group received anthracyclines. Hair loss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001). Three of 5 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27.3% (95% CI, 18.0%-36.6%) reported feeling

Full Text available with Trip Pro

2017 JAMA

17. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. (PubMed)

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial.To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects.Multicenter randomized clinical trial of women with breast

Full Text available with Trip Pro

2017 JAMA Controlled trial quality: predicted high

20. Alopecia areata

Alopecia areata Alopecia areata - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alopecia areata Last reviewed: February 2019 Last updated: November 2017 Summary Autoimmune disease that targets the hair follicle. Characterised by sudden onset of patchy hair loss. Diagnosis is clinical. Characteristic physical findings are exclamation mark hairs (short, broken hairs) and a positive pull test. A scalp biopsy shows (...) perifollicular inflammation. Topical or intralesional corticosteroids are appropriate for patients with limited hair loss. Skin atrophy can be a temporary side effect. Definition Alopecia areata (AA) is an autoimmune disease that affects almost 2% of the population in the US. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-633. http://www.ncbi.nlm.nih.gov/pubmed/7791384?tool=bestpractice.com Inflammatory cells

2017 BMJ Best Practice